cirmtuzumab

May 4, 2020May 4, 2020

Cirmtuzumab-Imbruvica Yields ‘Encouraging’ Response Rates Against Mantle Cell Lymphoma, Ongoing Trial Shows

News

Combination therapy with the investigational treatment cirmtuzumab plus Imbruvica (ibrutinib) led to “highly encouraging” response rates among patients with mantle cell lymphoma (MCL), a type of B-cell cancer, according to the ... Read more

October 31, 2019

Cirmtuzumab-Imbruvica Combo Trial Opens New Expansion Part for Mantle Cell Lymphoma

News

A Phase 1/2 trial assessing Oncternal Therapeutics‘ cirmtuzumab plus Imbruvica (ibrutinib) for the treatment of B-cell cancers is opening a Phase 1b extension part to continue studying the combination in people ... Read more

August 27, 2019

Cirmtuzumab-Imbruvica Combo Trial Enrolling CLL, SLL Patients for Phase 2

News

Following promising early efficacy results for a cirmtuzumab–Imbruvica treatment combo, a Phase 2 clinical trial has now been opened to people with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The opening of ... Read more

May 18, 2018May 18, 2018

1st Mantle Cell Lymphoma Patient Dosed in Phase 1/2 Trial Testing Cirmtuzumab-Imbruvica Combo

News

A Phase 1b/2 clinical trial evaluating Oncternal Therapeutics‘ investigational therapy cirmtuzumab in combination with Imbruvica (ibrutinib) for the treatment of B-cell malignancies has dosed its first patient with mantle cell lymphoma. The trial is ... Read more

September 19, 2017

UCSD Researchers Awarded $18.3M to Study New Combo Therapy for B-cell Cancers

News

The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine (CIRM) has aproved an $18.29 million grant to researchers at the University of California San Diego (UCSD) School ... Read more